thiotepa + gemcitabine + carboplatin

**thiotepa + gemcitabine + carboplatin** is a triple-agent chemotherapy combination regimen consisting of three distinct pharmaceuticals: thiotepa (an alkylating agent), gemcitabine (a nucleoside analog antimetabolite), and carboplatin (a platinum-based compound). Each agent interferes with DNA function and replication in distinct ways, targeting rapidly dividing cancer cells. Thiotepa introduces alkyl groups into DNA, leading to cross-linking and apoptosis. Gemcitabine incorporates into DNA and inhibits DNA synthesis via ribonucleotide reductase inhibition. Carboplatin produces DNA crosslinks through its platinum coordination, triggering cell death. While two-drug regimens such as gemcitabine + carboplatin are used for a range of solid tumors (including non-small cell lung cancer and other advanced malignancies[2][3][4][6][7]), addition of thiotepa is primarily reported for high-dose chemotherapy protocols prior to autologous stem cell transplantation in relapsed or refractory germ cell tumors and other severe malignancies[1]. No specific FDA-approved brand or clinical code uniquely identifies the triple combination; the regimen is typically prescribed in specialized oncology settings, often as part of investigational or salvage therapy.